11.10
Precedente Chiudi:
$11.41
Aprire:
$11.26
Volume 24 ore:
50,107
Relative Volume:
0.21
Capitalizzazione di mercato:
$110.07M
Reddito:
$6.39M
Utile/perdita netta:
$-117.26M
Rapporto P/E:
-0.889
EPS:
-12.4807
Flusso di cassa netto:
$-79.08M
1 W Prestazione:
-3.04%
1M Prestazione:
-4.70%
6M Prestazione:
-69.07%
1 anno Prestazione:
-52.99%
Korro Bio Inc Stock (KRRO) Company Profile
Nome
Korro Bio Inc
Settore
Industria
Telefono
617-468-1999
Indirizzo
60 FIRST STREET, CAMBRIDGE
Compare KRRO vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
|
KRRO
Korro Bio Inc
|
11.10 | 113.19M | 6.39M | -117.26M | -79.08M | -12.48 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.54 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.00 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
680.44 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
312.02 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
281.47 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Korro Bio Inc Stock (KRRO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-13 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2026-02-17 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2026-01-29 | Aggiornamento | Chardan Capital Markets | Neutral → Buy |
| 2026-01-29 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2026-01-29 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2026-01-28 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2026-01-28 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2025-11-13 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2025-11-13 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2025-11-13 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2025-11-13 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2025-11-13 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-11-13 | Downgrade | Raymond James | Strong Buy → Mkt Perform |
| 2025-11-13 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2025-04-29 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-04-16 | Iniziato | Chardan Capital Markets | Buy |
| 2025-01-10 | Iniziato | Oppenheimer | Outperform |
| 2024-10-21 | Iniziato | Raymond James | Strong Buy |
| 2024-08-14 | Iniziato | William Blair | Outperform |
| 2024-03-28 | Reiterato | H.C. Wainwright | Buy |
| 2024-02-27 | Iniziato | BMO Capital Markets | Outperform |
| 2023-12-04 | Iniziato | H.C. Wainwright | Buy |
| 2023-11-29 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-11-10 | Iniziato | Piper Sandler | Overweight |
| 2023-02-15 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2023-02-13 | Downgrade | Cowen | Outperform → Market Perform |
| 2021-09-22 | Downgrade | Goldman | Buy → Neutral |
| 2021-01-27 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2020-12-22 | Iniziato | B. Riley Securities | Buy |
| 2020-07-14 | Iniziato | Oppenheimer | Outperform |
| 2020-05-18 | Downgrade | JP Morgan | Overweight → Neutral |
| 2019-10-28 | Iniziato | Cowen | Outperform |
| 2019-10-28 | Iniziato | Goldman | Buy |
| 2019-10-28 | Iniziato | JP Morgan | Overweight |
Mostra tutto
Korro Bio Inc Borsa (KRRO) Ultime notizie
Korro Bio raises $85 million in private equity financing By Investing.com - Investing.com Nigeria
Korro Bio Stock Gains After Tough 2025New Drug Candidate, Analyst Upgrades Boost Outlook - Sahm
12 Health Care Stocks Moving In Friday's Pre-Market Session - Sahm
RBC Capital Keeps Their Hold Rating on Korro Bio (KRRO) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Solid Biosciences (SLDB), Korro Bio (KRRO) and Pharming Group (PHAR) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Korro Bio (KRRO), Oruka Therapeutics (ORKA) and Gilead Sciences (GILD) - The Globe and Mail
Analysts Are Bullish on These Healthcare Stocks: Korro Bio (KRRO), Health Catalyst (HCAT) - The Globe and Mail
Korro Bio (KRRO) Losses Of US$117.3 Million Test Bullish Narratives On Profitability - simplywall.st
Korro Bio (KRRO) sellers register 7.65M common shares after $85M private placement - Stock Titan
Cantor Fitzgerald raises Korro Bio stock price target on UCD confidence - Investing.com Canada
Raymond James upgrades Korro Bio stock rating on hyperammonemia pivot - Investing.com Nigeria
Raymond James upgrades Korro Bio stock rating on hyperammonemia pivot By Investing.com - Investing.com UK
Insider Buying: New Enterprise Associates 17, L.P. Acquires Addi - GuruFocus
Korro Bio, Inc. (KRRO) Reports Q4 Loss, Lags Revenue Estimates - sharewise.com
Nea 17 buys Korro Bio (KRRO) shares worth $2.3 million - Investing.com
Korro Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - Bitget
Korro Bio investor buys $2.3 million in KRRO stock By Investing.com - Investing.com
Advancing Genetic Medicines with RNA Editing: Inside the OPERA Platform and Therapeutic Strategies - Minichart
Korro Bio, Inc. (KRRO) reports Q4 loss, lags revenue estimates - MSN
Baskett Forest buys Korro Bio (KRRO) shares worth $2.3 million - Investing.com
Nea 17 buys Korro Bio (KRRO) shares worth $2.3 million By Investing.com - Investing.com South Africa
NEA 17 fund tied to Korro Bio (KRRO) buys 450K shares and warrants - Stock Titan
Insider fund tied to Carmen Chang boosts Korro Bio (KRRO) stake with 450,045 buys - Stock Titan
Korro 10-K: $6.4M Collaboration Revenue; $(12.48) EPS on $(117.3)M Net Loss - TradingView
Korro Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Korro Bio (NASDAQ: KRRO) expands RNA-editing pipeline as 2025 net loss deepens - Stock Titan
New RNA edit drug, $85M cash boost give Korro Bio runway to 2028 - Stock Titan
Korro Bio, Inc. (KRRO) Announces Fourth Quarter Loss, Falls Short of Revenue Expectations - Bitget
Korro shares jump 17% following $85M private placement financing - MSN
Korro Bio (KRRO) Projected to Post Quarterly Earnings on Tuesday - MarketBeat
Korro Secures $85M Lifeline After Trial Setback - National Today
Korro Bio Raises $85 Million in Oversubscribed PIPE Financing to Advance RNA Editing Therapies and Extend Cash Runway into 2028 - Minichart
Korro Bio extends cash runway after trial fail, layoffs - The Business Journals
Korro Announces $85 Million Private Placement - citybiz
Korro Bio prices 4.5M shares at $11.11 in private placement - TipRanks
Korro Announces Oversubscribed $85 Million Private Placement - Bitget
Korro Bio Announces Oversubscribed $85M PIPE Financing - TipRanks
Korro stock surges 17% on $85M private placement financing By Investing.com - Investing.com India
Korro Bio raises $85 million in private equity financing - Investing.com
Korro Bio Raises $85 Million in Private Placement, Adds Investor Registration Rights - TradingView
Korro stock surges 17% on $85M private placement financing - Investing.com
Korro Bio (KRRO) secures $85M PIPE to extend cash runway into 2028 - Stock Titan
Korro Bio, Inc. $KRRO Stock Position Raised by JPMorgan Chase & Co. - MarketBeat
Bond Watch: Does Korro Bio Inc have pricing powerJuly 2025 Reactions & Long-Term Safe Investment Plans - baoquankhu1.vn
Winners Losers: Should you avoid Korro Bio Inc stock right nowWeekly Earnings Recap & Reliable Volume Spike Trade Alerts - baoquankhu1.vn
Korro Bio, Inc. (NASDAQ:KRRO) Receives Consensus Rating of “Hold” from Analysts - Defense World
KRRO Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
KRRO Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Bond Watch: What is the next catalyst for Korro Bio IncTrade Volume Report & Precise Swing Trade Alerts - baoquankhu1.vn
Profit Recap: Will Korro Bio Inc benefit from green energy policiesQuarterly Market Summary & Breakout Confirmation Trade Signals - baoquankhu1.vn
Korro Bio (KRRO) price target increased by 12.61% to 19.53 - MSN
Korro Bio Inc Azioni (KRRO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Korro Bio Inc Azioni (KRRO) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| SANDELL SCOTT D | 10% Owner |
Mar 10 '26 |
Buy |
11.11 |
207,100 |
2,300,881 |
1,297,893 |
| New Enterprise Associates 17, | 10% Owner |
Mar 10 '26 |
Buy |
11.11 |
207,100 |
2,300,881 |
1,297,893 |
| Chang Carmen | 10% Owner |
Mar 10 '26 |
Buy |
11.11 |
207,100 |
2,300,881 |
1,297,893 |
| BASKETT FOREST | 10% Owner |
Mar 10 '26 |
Buy |
11.11 |
207,100 |
2,300,881 |
1,297,893 |
| Mathers Edward T | 10% Owner |
Mar 10 '26 |
Buy |
11.11 |
207,100 |
2,300,881 |
1,297,893 |
| Makhzoumi Mohamad | 10% Owner |
Mar 10 '26 |
Buy |
11.11 |
207,100 |
2,300,881 |
1,297,893 |
| Walker Paul Edward | 10% Owner |
Mar 10 '26 |
Buy |
11.11 |
207,100 |
2,300,881 |
1,297,893 |
| Florence Anthony A. Jr. | 10% Owner |
Mar 10 '26 |
Buy |
11.11 |
207,100 |
2,300,881 |
1,297,893 |
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):